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Background: The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3,
and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.
Methods: The expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 messenger RNA (mRNA)
in 108 cases of cancer tissue and adjacent tissue in patients with pancreatic cancer was detected by reverse
transcriptase polymerase chain reaction (RT-PCR). Expression of SSTR-2, SSTR-3, and SSTR-5 mRNA was evaluated
after specimens were taken from selected patients who underwent surgical resection by Whipple’s operation.
We speculated the clinical significance of the expression of somatostatin receptor (SSTR) subtype genes SSTR-2,
SSTR-3, and SSTR-5 in pancreatic tissue and non-cancerous tissue and further elucidated their clinical significance.
Results: The expression rates of SSTR-2 mRNA in cancer and adjacent tissue of 108 patients with pancreatic cancer
were 81.5% (88/108) and 97.2% (105/108), respectively; SSTR-3 mRNA expression rates were 69.4% (75/108) and 55.6%
(60/108). SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).
Conclusion: We propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer
undergoing somatostatin or its analog therapy.
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Somatostatin is a type of peptide hormone which has a
wide range of biological functions. Recent studies have
indicated that somatostatin and its analogs have obvious
anti-proliferative effects on various solid tumors, such as
gastroenteropancreatic neuroendocrine tumors and breast
cancer, which are mediated through somatostatin recep-
tors [1,2], but some clinical research have indicated that
the impact of somatostatin and its analog receptor expres-
sion levels on outcomes in patients with pancreatic neuro-
endocrine tumors (PNETs) has not been evaluated [3,4].
Thus, whether or not there is expression of somatostatin
receptor (somatostatin receptor, SSTR) in tumor tissue
is an important underlying factor affecting the efficacy
of somatostatin therapy. In this study, we detected the* Correspondence: sdusurg@gmail.com
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unless otherwise stated.expression of somatostatin receptor subtypes SSTR-2,
SSTR-3, and SSTR-5 messenger RNA (mRNA) from 108
cases of cancer tissue and adjacent tissue in patients with
pancreatic cancer using RT-PCR method. Thereafter, we
explored the clinical implications of somatostatin therapy
for patients with pancreatic cancer. Our study is aimed at
exploring the cause from different therapeutic effects of
somatostatin and its analogs on human pancreatic cancer
and their relationship between changes of SSTR-2 gene ex-
pression and expression of SSTR-2, SSTR-3, and SSTR-5
genes [5].Methods
Patient population and data collection
Our study was a retrospective analysis of patients who
had been diagnosed pathologically as having pancreatic
ductal adenocarcinoma by the Department of Pathology
in Qilu hospital, between January 2010 and June 2013.
The demographic, clinical, laboratory, and radiologicall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with a diagnosis of pancreatic ductal adenocarcinoma
were reviewed retrospectively for this study. Included in
this study, patients with pancreatic cancer must have re-
ceived surgical resection as the initial treatment modality
without major perioperative complications, have adequate
archived tissue kept, and have complete clinicopathologic
data obtained. This resulted in a collection of tissue from
108 patients, 72 males and 36 females with a median age
of 55.7 years and an age range of 33 to 71 years. Among
those, 85 had cases of carcinoma of the head of the pan-










Gender P < 0.05**
Male 56 40 16
Female 52 48 4
Age (years) P > 0.05





≥60 68 53 15
T stage P > 0.05
T1 1 0 1
T2 13 11 2
T3 45 36 9
T4 49 41 8
N stage P > 0.05
N0 63 53 10
N1 34 28 6
N2 11 7 4
M stage P > 0.05
M0 84 67 17
M1 24 21 3
TNM stage P > 0.05
I to II 40 31 9
III to IV 68 57 11
Differentiation P > 0.05
Well 40 33 7
Moderate 45 35 10




Death 90 70 20
Censored 18 18 0
The expression of SSTR-2 was significantly relevant with the survival rate. The surviv
expression (P < 0.05*). The expressions of SSTR-2 mRNA and SSTR-3 mRNA were releva
(P < 0.05**). These three kinds of mRNA expression had no obvious relationshipthe pancreas. For UICC TNM clinical stages: stages I to II
had 33 cases, and stages III to IV had 75 cases. We also
collected the non-cancerous pancreatic tissue from 10
patients (all by excision of the normal pancreas were
taken from surgical specimens) in order to compare the
mRNA expression rate with the cancerous pancreatic tis-
sues and adjacent normal tissue. The pathologic tumor-
node-metastasis (TNM) classification was based on the
criteria of the International Union Against Cancer (2009).
The study protocol was approved by the Ethics Committee
of Qilu Hospital affiliated to Shandong University. In-









P < 0.05** P > 0.05
33 23 8 48
42 10 6 46




48 20 9 59
P > 0.05 P > 0.05
0 1 0 1
9 5 2 11
35 10 5 40
32 17 7 42
P > 0.05 P > 0.05
42 21 7 56
25 9 5 29
8 3 2 9
P > 0.05 P > 0.05
58 26 9 75
17 7 5 19
P > 0.05 P > 0.05
27 13 6 34
48 20 8 60
P > 0.05 P > 0.05
30 10 4 36
29 16 5 40
16 7 5 18
P > 0.05 P > 0.05
63 27 11 79
12 6 3 15
al rate of patients with positive expression was higher than those with negative
nt with gender. Female positive rate was significantly higher than male
s with age, TNM stage, and differentiation (P > 0.05).
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detailed case characteristics are summarized in Table 1.Reagents
Total RNA extraction reagents were bought from Promega
(Madison, WI, USA). Specific primers, RT-PCR reagents
and restriction enzymes, were provided by TaKaRa (Bio
Company, Kyoto, Japan).Specimen collection
Non-necrotic cancer tissue and adjacent normal tissue
(3 cm from cancer tissue) were taken from surgical spec-
imens (non-cancerous pancreatic tissues were taken
from the normal tissue). All were frozen in liquid nitro-
gen immediately after removal and placed in −80°C.Table 3 SSTR-2, SSTR-3, and SSTR-5 mRNA expression in
different tissues
Tissue Positive (n) Negative (n) Total PositiveRT-PCR
Complementary DNA (cDNA) was synthesized by reverse
transcription of 20 μl total RNA in a reaction system.
Following reaction system was used: MgCl2 5 mmol/L,
dNTPs 5 mmol/L, RNAsin 20U, AMV reverse transcript-
ase XL2.5U, oligo d (T) adaptor primers 2.5 μmol/L. The
reaction was carried out at 65°C for 10 min; after cooling
at 4°C for 5 min, AMV reverse transcriptase Xl was added
and then incubated at 42°C for 60 min, 99°C heating for
5 min to inactivate the reverse transcriptase. PCR was per-
formed using the following schedule: 30 cycles of denatur-
ation at 94°C for 30 s; annealing of SSTR-2 and SSTR-5 at
57°C for 30 s and SSTR-3 at 63°C for 60 s; positive control
at 60°C for 30 s; extension at 72°C for 1 min; frozen at 4°C
for 5 min. Special primer pairs were listed as supplemen-
tary Table 2.Table 2 Special primer pairs for amplifying human SSTR-2,
SSTR-3, and SSTR-5 subtypes by RT-PCR
Primers Sequences of primers Size of PCR
products (bp)
SSTR-2
Sense 5′-CATCATTGGGTTGTGTGCA-3′ (162 to 181) 256
Antisense 5′-GCTCGATGCTCATGACTGTC-3′ (399 to 418)
SSTR-3
Sense 5′-TGGCATTGGGTTGTTCATG-3′ (263 to 282) 435
Antisense 5′-CTTCACCAGGGTTGTGTGTAG-3′ (675 to 696)
SSTR-5
Sense 5′-GTTCATTGGGTTGTGTGCG-3′ (169 to 187) 101




All statistical data was evaluated by χ2 test. The P < 0.05
was considered statistically significant while three
samples were compared. While comparing two sam-
ples, we used partitions of χ2 method to significant level
α’. α’ = α/((k − 1) × k/2 + 1) (k, numbers of combination of
any two). We could calculate the outcome of α’ is 0.0125.
Thus, P < 0.0125 was considered statistically significant.
Survival analyses were conducted by the life table method
and the log-rank test. P values <0.05 were considered to
be statistically significant. Survival curves were generated
through the life table method.
Results
In 108 cases of pancreatic cancer patients, the expression
rate of SSTR-2 receptor mRNA in adjacent cancer tissues
was 97.2% (105/108) and in cancer tissue was 81.5%
(88/108) (Table 3). The rate of positive SSTR-2 mRNA ex-
pression among carcinous tissue, adjacent tissue of cancer,
and non-carcinous pancreatic tissues were significantly
different via analysis (P < 0.01). When compared between
any two groups, the difference between carcinous tissue
and adjacent tissue was also significant. Positive expres-
sion in carcinous tissue was also higher than adjacent tis-
sue (P < 0.0125) (Table 3). Analysis from other groups did
not show obvious differences (P > 0.0125). The expression
rate of SSTR-3 receptor mRNA in adjacent cancer tis-
sue was 55.6% (60/108). In cancer tissue, it was 69.4%
(75/108) (Table 3). The expression rate of SSTR-5 recep-
tor mRNA in adjacent cancer tissues was 18.5% (20/108).rate
SSTR-2 mRNA expression
Carcinous tissues
88 20 108 81.5%
Adjacent cancerous tissues 105 3 108 97.2%
Non-carcinous pancreatic
tissues
10 0 10 100%
Total 203 23 226 89.8%
SSTR-3 mRNA expression
Carcinous tissues
75 33 108 69.4%
Adjacent cancerous tissues 60 48 108 55.6%
Non-carcinous pancreatic
tissues
7 3 10 70%
Total 142 84 226 62.8%
SSTR-5 mRNA xpression
Carcinous tissues
14 94 108 13.0%
Adjacent cancerous tissues 20 88 108 18.5%
Non-carcinous pancreatic
tissues
1 9 10 10%
Total 35 191 226 15.5%
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SSTR-3, and SSTR-5 mRNA expression rate of ten cases
of non-cancerous pancreatic tissue were 100.0% (10/10),
70.0% (7/10), and 10.0% (1/10) (Table 2).
No significant differences were showed among three
groups or the combination of any two groups via χ2 tests.
Thus, we could draw a conclusion that the SSTR-3 mRNA
expression among carcinous tissue, adjacent tissue of can-
cer, and non-carcinous tissue were similar (Table 4).
We concluded that the expression of SSTR-2 was sig-
nificantly associated with survival rates (Table 1). The
survival rate of patients with a positive expression was
higher than those with a negative expression (P < 0.05*).
The expression of SSTR-2 mRNA and SSTR-3 mRNA
were relevant with gender. The female positive rate
was significantly higher than males (P < 0.05**). These
three kinds of mRNA’s expressions had no obvious re-
lationships with age, TNM stage, and cancer differen-
tiation (P > 0.05).
Survival curves are shown in Figure 1a-c. Patients with
positive SSTR-2 mRNA expression in carcinous tissue
had a significantly better overall survival rate than those
with negative expression (P < 0.05, the log-rank test, χ2 =
4.40). The difference of a patients’ survival rate between
positive and negative SSTR-3 expression in carcinous tis-
sue had no statistical significance (P > 0.05, the log-rank
test, χ2 = 0.003), and the difference of a patients’ survival
rate between positive and negative SSTR-5 expression in
carcinous tissue also had no statistical significance (P >
0.05, the log-rank test, χ2 = 0.391).Table 4 The χ2 test outcomes of SSTR-2, SSTR-3, and
SSTR-5 mRNA expression
Samples χ2 P
SSTR-2 mRNA expression Three groups 15.82 P < 0.01
Carcinous tissues and adjacent cancerous
tissues cancer
14.06 P < 0.0125
Carcinous tissues and non-carcinous tissues 2.23 P > 0.0125
Adjacent cancerous tissues and non-carcinous
tissues
0.29 P > 0.0125
SSTR-3 mRNA expression Three groups 4.69 P > 0.05
Carcinous tissues and adjacent cancerous
tissues
4.44 P > 0.0125
Carcinous tissues and non-carcinous tissues 0.0013 P > 0.0125
Adjacent cancerous tissues and non-carcinous
tissues
0.78 P > 0.0125
SSTR-5 mRNA expression Three groups 1.51 P > 0.05
Carcinous tissues and adjacent cancerous
tissues
1.26 P > 0.0125
Carcinous tissues and non-carcinous tissues 0.07 P > 0.0125
adjacent cancerous tissues and non-carcinous
tissues
0.45 P > 0.0125
Figure 1 Overall survival according to SSTR-2,SSTR-3,SSTR-5
mRNA expression in pancreatic cancer patients. (a) Overall
survival according to SSTR-2 mRNA expression in pancreatic cancer
patients. (b) Overall survival according to SSTR-3 mRNA expression in
pancreatic cancer patients. (c) Overall survival according to SSTR-5
mRNA expression in pancreatic cancer patients.Discussion
Somatostatin can inhibit growth of pancreatic cancer cells
even in CPT-insensitive human pancreatic carcinoid BON
cells [6]. The inhibition mechanism involves the combined
interaction of somatostatin and its analogs with SSTR-2 in
tumor tissues, mainly through binding to tumor tissue re-
ceptors [7], which directly inhibits tumor cell proliferation.
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ing division and proliferation of tumor cells or inhibiting
the activity of various growth factors, such as vascular
endothelial growth factor (VEGF), insulin-like growth fac-
tor (IGF) and marked stimulation of the reticuloendothe-
lial system [8,9]. Moreover, it counteracts tumorigenesis
and tissue proliferation. In addition, it was found that
somatostatin and its analogs could arrest the pancreatic
cancer cell cycle at S phase and thus induce apoptosis
[10]. In cloned somatostatin receptor subtypes, synthetic
long-acting somatostatin analogs 6 or 8, such as octreotide
and vapreotide have high affinity to SSTR-2 and SSTR-5
receptor subtypes, low affinity to SSTR-3, and no affinity
to other types of receptor subtypes [11]. Therefore, before
implementing therapy by long-acting somatostatin analogs
such as octreotide in pancreatic cancer patients, to make
sure that tumor tissue have high affinity somatostatin
receptors, it is important to improve efficacy and reduce
unnecessary costs. There is genre and organ specificity
in the expression of somatostatin receptors; for example,
the normal pancreas mainly expresses SSTR-2 subtype
receptors, while only SSTR-3 genes are expressed in
rat pancreatic tissue; in the outer periphery of the body
organization, only SSTR-5 subtype receptors are found in
the hypothalamus and pituitary tissue [12]. Therefore, in
relation to drug receptor binding affinity and organ-
specific aspects, we studied SSTR-2, SSTR-3, and SSTR-5
expression in the pancreatic cancer.
There are few reports about research on somatostatin
receptor gene expression in pancreatic tumor tissue.
Somatostatin receptor expression in pancreatic tissue is
detected by using isotopically labeled somatostatin [13].
However, because natural or synthetic somatostatin can
bind to various somatostatin receptors, we cannot deter-
mine which kind of somatostatin subtype receptor binds
to isotopically labeled somatostatin. RT-PCR assay has
good specificity and high sensitivity for detection of
SSTR-2 gene expression in tumor specimens.
From the results of this study, there were 88 cases
with positive expression of SSTR-2 mRNA out of 108
pancreatic cancer cases; thus, the rate was 81.5%. This
shows that the majority of pancreatic tumor tissues have
SSTR-2 receptor subtype expression. Because the current
study shows that the ability of somatostatin to inhibit
tumor cell growth is mediated by SSTR-2 [14,15], it is very
important for patients suffering from pancreatic cancer to
receive somatostatin treatment. In experimental pan-
creatic tumor, the growth of both functioning pancre-
atic tumors and nonfunctioning tumors with SSTR-2
gene expression is inhibited by somatostatin, while there
is no inhibitory effect on non-SSTR-2 gene expression
cells. Carcinoid patients had a similar situation [16]. Re-
searchers believe that the expression of SSTR-2 in tumor
tissue is the premise for patients to accept somatostatintherapy. In addition, SSTR-3 mRNA expression was higher
in pancreatic tumor tissue than the adjacent tissue of can-
cer, and the rate of positive expression decreases with in-
creasing degree of differentiation trend. Significance of
pancreatic tissue SSTR-3 mRNA expression is still unclear.
Compared with SSTR-2, SSTR-3 has low affinity when
compared to six or eight peptide long-acting somatostatin
analogs, so further study is needed to determine its role in
the treatment of tumors.
There is less difference in the rate of SSTR-5 mRNA
expression in pancreatic tumor tissue and tumor adja-
cent tissue, both were low, which is consistent with pre-
vious findings [17]. Synthetic six or eight long-acting
somatostatin analogs like octreotide and vapreotide have
high affinity to the SSTR-5 receptor subtype [10]; its spe-
cific mechanism in pancreatic cancer remains to be fur-
ther explored.
Conclusions
In summary, our findings indicated that the majority of
pancreatic cancers have more than one somatostatin re-
ceptor subtype gene. According to recent studies, we ob-
tained that somatostatin and its analogs have obvious
anti-proliferative effects on various solid tumors which are
mediated through somatostatin receptors. We propose
that the SSTR-2 could play an important role in clinical
implications for patients with pancreatic cancer undergo-
ing somatostatin or its analog therapy.
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